Group exercise may keep aging brains and bodies in shape
NCT ID NCT07494149
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study tests a 16-week group exercise program called the Ideomotor Program in 158 healthy adults aged 50 and older. The program combines physical and mental exercises to see if it improves thinking, movement, and overall well-being. Participants will be compared to a group doing standard cognitive training.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- Active substance
- Ideomotor Group Exercise Program
- What this could lead to
- If it works, this could offer a simple, social exercise program to help older adults stay sharp, steady, and happy.
- What could go wrong
- This is a small, early-stage trial in healthy volunteers. The exercise program may not improve thinking or movement more than standard activities, and results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre for Healthy Longevity
RECRUITINGBergamo, Bergamo, 24129, Italy
-
University of Bergamo - S. Agostino
NOT_YET_RECRUITINGBergamo, BG, 24124, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test